Cargando…

Molecular Signatures of a TLR4 Agonist-Adjuvanted HIV-1 Vaccine Candidate in Humans

Systems biology approaches have recently provided new insights into the mechanisms of action of human vaccines and adjuvants. Here, we investigated early transcriptional signatures induced in whole blood of healthy subjects following vaccination with a recombinant HIV-1 envelope glycoprotein subunit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Anderson, Jenna, Olafsdottir, Thorunn A., Kratochvil, Sven, McKay, Paul F., Östensson, Malin, Persson, Josefine, Shattock, Robin J., Harandi, Ali M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834766/ https://www.ncbi.nlm.nih.gov/pubmed/29535712 http://dx.doi.org/10.3389/fimmu.2018.00301

Ejemplares similares

C-type lectin receptor agonists elicit functional IL21-expressing Tfh cells and induce primary B cell responses in neonates
por: Vono, Maria, et al.
Publicado: (2023)

Chemokine-Adjuvanted Plasmid DNA Induces Homing of Antigen-Specific and Non–Antigen-Specific B and T Cells to the Intestinal and Genital Mucosae
por: Aldon, Yoann, et al.
Publicado: (2020)

Comparative Systems Analyses Reveal Molecular Signatures of Clinically tested Vaccine Adjuvants
por: Olafsdottir, Thorunn A., et al.
Publicado: (2016)

Evaluation of TLR Agonists as Potential Mucosal Adjuvants for HIV gp140 and Tetanus Toxoid in Mice
por: Buffa, Viviana, et al.
Publicado: (2012)

TLR4 and TLR7/8 Adjuvant Combinations Generate Different Vaccine Antigen-Specific Immune Outcomes in Minipigs when Administered via the ID or IN Routes
por: McKay, Paul F., et al.
Publicado: (2016)

Molecular signatures of anthroponotic cutaneous leishmaniasis in the lesions of patients infected with Leishmania tropica
por: Masoudzadeh, Nasrin, et al.
Publicado: (2020)

Nasal Immunization Confers High Avidity Neutralizing Antibody Response and Immunity to Primary and Recurrent Genital Herpes in Guinea Pigs
por: Persson, Josefine, et al.
Publicado: (2016)

Corrigendum: Immunoglobulin G1 Allotype Influences Antibody Subclass Distribution in Response to HIV gp140 Vaccination
por: Kratochvil, Sven, et al.
Publicado: (2018)

Immunoglobulin G1 Allotype Influences Antibody Subclass Distribution in Response to HIV gp140 Vaccination
por: Kratochvil, Sven, et al.
Publicado: (2017)

Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 Agonist, Promotes Potent Systemic and Mucosal Responses to Intranasal Immunization with HIVgp140
por: Arias, Mauricio A., et al.
Publicado: (2012)

Using distinct molecular signatures of human monocytes and dendritic cells to predict adjuvant activity and pyrogenicity of TLR agonists
por: Kamgang, Richard Kenmoe, et al.
Publicado: (2008)

TLR Agonists as Vaccine Adjuvants Targeting Cancer and Infectious Diseases
por: Luchner, Marina, et al.
Publicado: (2021)

Antigen-specific T lymphocyte responses elicited by a DNA – MVA HIV CN54gp140 immunization regime are significantly altered by the TLR4 adjuvant GLA
por: McKay, PF, et al.
Publicado: (2012)

Exploration of Pattern Recognition Receptor Agonists as Candidate Adjuvants
por: Ong, Guang Han, et al.
Publicado: (2021)

A novel defined TLR3 agonist as an effective vaccine adjuvant
por: Ko, Kwang Hyun, et al.
Publicado: (2023)

Optimisation of ex vivo memory B cell expansion/differentiation for interrogation of rare peripheral memory B cell subset responses
por: Muir, Luke, et al.
Publicado: (2018)

BBIQ, a pure TLR7 agonist, is an effective influenza vaccine adjuvant
por: Kaushik, Deepender, et al.
Publicado: (2020)

Combination of STING and TLR 7/8 Agonists as Vaccine Adjuvants for Cancer Immunotherapy
por: Bhatnagar, Shubhmita, et al.
Publicado: (2022)

Differential Adjuvant Activities of TLR7 and TLR9 Agonists Inversely Correlate with Nitric Oxide and PGE(2) Production
por: Lee, Jinhee, et al.
Publicado: (2015)

The TLR7 agonist imiquimod as an adjuvant for radiotherapy-elicited in situ vaccination against breast cancer
por: Demaria, Sandra, et al.
Publicado: (2013)

Synthetic Toll Like Receptor-4 (TLR-4) Agonist Peptides as a Novel Class of Adjuvants
por: Shanmugam, Arulkumaran, et al.
Publicado: (2012)

Molecular and Cellular Response Profiles Induced by the TLR4 Agonist-Based Adjuvant Glucopyranosyl Lipid A
por: Lambert, Stacie L., et al.
Publicado: (2012)

Synthetic glycan-based TLR4 agonists targeting caspase-4/11 for the development of adjuvants and immunotherapeutics
por: Adanitsch, Florian, et al.
Publicado: (2018)

An Overview of Recent Insights into the Response of TLR to SARS-CoV-2 Infection and the Potential of TLR Agonists as SARS-CoV-2 Vaccine Adjuvants
por: Kayesh, Mohammad Enamul Hoque, et al.
Publicado: (2021)

A Dual TLR Agonist Adjuvant Enhances the Immunogenicity and Protective Efficacy of the Tuberculosis Vaccine Antigen ID93
por: Orr, Mark T., et al.
Publicado: (2014)

New chimeric TLR7/NOD2 agonist is a potent adjuvant to induce mucosal immune responses
por: Gutjahr, Alice, et al.
Publicado: (2020)

Lipid A Mimetics Based on Unnatural Disaccharide Scaffold as Potent TLR4 Agonists for Prospective Immunotherapeutics and Adjuvants
por: Strobl, Sebastian, et al.
Publicado: (2022)

New Glucosamine-Based TLR4 Agonists: Design, Synthesis, Mechanism of Action, and In Vivo Activity as Vaccine Adjuvants
por: Romerio, Alessio, et al.
Publicado: (2023)

Unraveling Molecular Signatures of Immunostimulatory Adjuvants in the Female Genital Tract through Systems Biology
por: Lindqvist, Madelene, et al.
Publicado: (2011)

Deoxyguanosine is a TLR7 agonist
por: Davenne, Tamara, et al.
Publicado: (2019)

NOD2 Agonist Promotes the Production of Inflammatory Cytokines in VSMC in Synergy with TLR2 and TLR4 Agonists
por: Sun, Jinghua, et al.
Publicado: (2012)

The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for T(H)1 Induction
por: Cauwelaert, Natasha Dubois, et al.
Publicado: (2016)

A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines
por: Van Hoeven, Neal, et al.
Publicado: (2017)

Alum Adjuvant and Built-in TLR7 Agonist Synergistically Enhance Anti-MUC1 Immune Responses for Cancer Vaccine
por: Zhou, Shi-Hao, et al.
Publicado: (2022)

Development of a TLR7/8 agonist adjuvant formulation to overcome early life hyporesponsiveness to DTaP vaccination
por: Dowling, David J., et al.
Publicado: (2022)

Structural Components for Amplification of Positive and Negative Strand VEEV Splitzicons
por: Blakney, Anna K., et al.
Publicado: (2018)

Distinct immune signatures in directly treated and distant tumors result from TLR adjuvants and focal ablation
por: Chavez, Michael, et al.
Publicado: (2018)

Intradermal immunisation using the TLR3-ligand Poly (I:C) as adjuvant induces mucosal antibody responses and protects against genital HSV-2 infection
por: Bardel, Emilie, et al.
Publicado: (2016)

Comparison of human B cell activation by TLR7 and TLR9 agonists
por: Hanten, John A, et al.
Publicado: (2008)

Specific activation of the TLR1-TLR2 heterodimer by small-molecule agonists
por: Cheng, Kui, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_r10vhqfsdrgcgb9d8brtnb1l7b